Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation

Proteasome inhibitors have become the standard of care for multiple myeloma. Blocking protein degradation particularly perturbs the homeostasis of short-lived polypeptides such as transcription factors and epigenetic regulators. To determine how proteasome inhibitors directly impact gene regulation,...

Descripción completa

Detalles Bibliográficos
Autores principales: Maneix, Laure, Iakova, Polina, Moree, Shannon E., Hsu, Joanne I., Mistry, Ragini M., Stossi, Fabio, Lulla, Premal, Sun, Zheng, Sahin, Ergun, Yellapragada, Sarvari V., Catic, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949381/
https://www.ncbi.nlm.nih.gov/pubmed/36846090
http://dx.doi.org/10.1158/2767-9764.CRC-22-0255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949381/
https://www.ncbi.nlm.nih.gov/pubmed/36846090
http://dx.doi.org/10.1158/2767-9764.CRC-22-0255

Ejemplares similares